With two months remaining in 2018, the US FDA’s drug center has already exceeded last year’s record approval count, with no signs of a slow-down on the horizon.
Shionogi & Co. Ltd. and Roche’s Xofluza became the forty-seventh novel agent cleared this year by the Center...